ImmunogenX, a clinical stage biotherapeutics company, has published the results of their phase 2 trial testing latiglutenase—an orally administered treatment for celiac disease (CD). Latiglutenase was shown to be safe and effective in reducing the symptoms of seropositive celiac disease patients on a gluten-free diet. A significant improvement in both symptom severity and quality of…
Continue ReadingIn this Los Angeles Times Op-Ed, Dr. Peter Green and Rory Jones, authors of “Gluten Exposed: The Science Behind the Hype” and CDF 2016 National Conference Key Note speakers, describe the serious health risks incurred by those following a gluten-free diet for non-medical reasons. “We bake our own pastry, gluten is now Satan” reads a knowing…
Continue ReadingLast month, the Celiac Disease Foundation had the privilege of sponsoring the 2024 International Celiac Disease Symposium in Sheffield, UK. As the first patient advocate invited to chair and present on a scientific panel, CEO Marilyn Geller co-chaired the End Points in Clinical Trials session with Dr. Francisco Leon, CEO...